ID
Cardiac Pacemaker Infection
search
Cardiac Pacemaker Infection
, Pacemaker Infection, Implanted Cardiac Defibrillator Infection
See Also
Cardiac
Pacemaker
Implanted Cardiac
Defibrillator
Endocarditis
Epidemiology
Device infections increased nearly 4 fold since 1990 as of 2006
Implants on older patients with comorbidities with more frequent revisions
Nearly 31,000 device infections per year in United States
Nearly two thirds are under-treated without device extraction, with a higher mortality and endocarditis risk (see below)
Risk of infection based on device status
Replacement device infection rate: 3%
New device implant infection rate: 1%
Existing device, late infection rate: 0.8%
Precautions
Pacemaker
s must be removed for either early or late infections
Do not aspirate or incise and drain the pocket
Assume endocarditis (associated with high mortality) in febrile
Pacemaker
patients
Pocket infections have mortality rate as high as 20%
Biofilm infections are more common and with higher rates of
Antibiotic Resistance
Risk Factors
Occult Implant Infection as source of
Staphylococcus aureus
Bacteremia
Relapsing bacteremia after appropriate
Antibiotic
s
No identified source for bacteremia
Bacteremia persists >24 hours
ICD Implant
Prosthetic Cardiac Valve
present
Bacteremia within 3 months of device placement
(2010) PACE 33(4): 407-13 [PubMed]
Pathophysiology
Organisms
Staphylococcus aureus
(most common)
Other
Gram Positive
infections
Coagulase negative
Staphylococcus
Enterococcus
species
Assorted
Streptococcus
species (Beta hemolytic strep, pneumococcus, Strep viridans)
Gram Negative Bacteria
E. coli
(45%)
Klebsiella
(20%)
Pseudomonas
(16%)
References
(2010) Circ Arrhythm Electrophysiol 3:639-45 [PubMed]
Types
Early infection
Presents with localized erythema, swelling, purulent discharge within weeks of
Pacemaker
placement
Infections occur more often in
Diabetes Mellitus
, post-placement
Hematoma
or with
Defibrillator
placement
Late infection
Most infections occur with one year of implantation
Typically
Staphylococcus
infections (50%
MRSA
)
Gram Negative Bacteria
and fungal infections are less common
Presents with insidious, slowly developing infection; may only demonstrate an overlying
Skin Erosion
Infections occur more often after
Pacemaker
manipulations (with 1-3% risk with each manipulation)
Endocarditis should be assumed (
Blood Culture
s are positive in 70% of cases, see below)
Evaluation
Palpate the
Pacemaker
pocket for tenderness, fluctuance suggestive of infection
Bedside Ultrasound
can detect
Pacemaker
pocker fluid collection
Labs
Obtain
Blood Culture
s (3 sets)
Diagnostics
Echocardiogram
Evaluate for valvular vegetation
PET Scan
Can highlight pocket infections
Management
Consult cardiology, infectious disease and surgery
Device removal recommended in all cases
Diagnosis may be unclear in early cases (pocket
Hematoma
or inflammation versus infection)
Some may opt for early empiric doxycyline course under close interval observation
Device removal if recurrent symptoms or signs after
Antibiotic
course
Conservative management of infection (without immediate device removal) is associated with increased mortality
Thirty day mortality is increased 7 fold over early device removal
One year mortality is increased 3 fold over early device removal
(2011) Heart Rhythm 8:1678-85 [PubMed]
Start empiric
Antibiotic
s after
Blood Culture
s (adult dosing shown)
Antibiotic
course
Pocket infection: 10-14 days
Lead associated endocarditis: 4-6 weeks (organism specific recommendations exist)
MRSA
Vancomycin
15-20 mg/kg IV q8-12 hours (or
Daptomycin
8-10 mg/kg q24 h) AND
Rifampin
300 mg orally twice daily
MSSA
Nafcillin
2 g IV every 4 hours OR
Cefazolin
2 g IV every 8 hours
References
(2016) Sanford Guide, accessed 3/7/2016
Prevention
Prophylactic
Antibiotic
s are not currently recommended at the time of device implantation
Baddour (2010) Circulation [PubMed]
References
(2018)
Cardiac Arrhythmia
Conference, UMN, Minneapolis
Jones and Orman in Majoewsky (2012) EM:Rap 12(5): 4-6
Mallemat, Swaminathan and Egan in Herbert (2014) EM:Rap 14(10): 5-7
Vanlandingham (2015) Crit Dec Emerg Med 29(10): 2-14
Type your search phrase here